Considerations for the Use of Imaging Tools for Phase II Treatment Trials in Oncology

被引：44
作者：
Shankar, Lalitha K. [1 ]
den Abbeele, AnnickVan [2 ]
Yap, Jeff [2 ]
Benjamin, Robert [3 ]
Scheutze, Scott [4 ]
FitzGerald, T. J. [5 ]
机构：
[1] NCI, Div Canc Treatment & Diag, Bethesda, MD 20892 USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[4] Univ Michigan Hlth Syst, Ann Arbor, MI USA
[5] Qual Assurance Review Ctr, Providence, RI USA
来源：
CLINICAL CANCER RESEARCH | 2009年 / 15卷 / 06期
关键词：
POSITRON-EMISSION-TOMOGRAPHY; GASTROINTESTINAL STROMAL TUMORS; IMATINIB MESYLATE; FDG-PET; END-POINTS; THERAPY; CHEMOTHERAPY; EFFICACY; SAFETY; CT;
D O I：
10.1158/1078-0432.CCR-08-2030
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
In the context of assessing tumor response, imaging tools have the potential to play a vital role in phase II and III treatment trials. If the imaging test is able to predict potential phase III success in a reliable fashion, it would be a useful tool in phase II trial design as it may provide for a more rapid and timely response assessment. The benefits and challenges of using anatomic imaging measures as well as the promising molecular imaging measures, primarily fluorodeoxyglucose-positron emission tomography, are discussed here. The general issues related to successful implementation of advanced imaging in the context of phase II treatment trials are discussed.
引用
收藏
页码：1891 / 1897
页数：7
相关论文
共 31 条
  • [1] Novel Designs and End Points for Phase II Clinical Trials
    Adjei, Alex A.
    Christian, Michaele
    Ivy, Percy
    [J]. CLINICAL CANCER RESEARCH, 2009, 15 (06) : 1866 - 1872
  • [2] We should desist using RECIST, at least in GIST
    Benjamin, Robert S.
    Choi, Haesun
    Macapinlac, Homer A.
    Burgess, Michael A.
    Patel, Shreyaskumar R.
    Chen, Lei L.
    Podoloff, Donald A.
    Charnsangavej, Chuslip
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (13) : 1760 - 1764
  • [3] CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: A quantitative analysis correlated with FDG PET findings
    Choi, H
    Charnsangavej, C
    Faria, SD
    Tamm, EP
    Benjamin, RS
    Johnson, MM
    Macapinlac, HA
    Podoloff, DA
    [J]. AMERICAN JOURNAL OF ROENTGENOLOGY, 2004, 183 (06) : 1619 - 1628
  • [4] Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: Proposal of new computed tomography response criteria
    Choi, Haesun
    Charnsangavej, Chuslip
    Faria, Silvana C.
    Macapinlac, Homer A.
    Burgess, Michael A.
    Patel, Shreyaskumar R.
    Chen, Lei L.
    Podoloff, Donald A.
    Benjamin, Robert S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (13) : 1753 - 1759
  • [5] Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas
    DeLaney, TF
    Spiro, IJ
    Suit, HD
    Gebhardt, MC
    Hornicek, FJ
    Mankin, HJ
    Rosenberg, AL
    Rosenthal, DI
    Miryousefi, F
    Ancukiewicz, M
    Harmon, DC
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2003, 56 (04): : 1117 - 1127
  • [6] Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
    Demetri, GD
    von Mehren, M
    Blanke, CD
    Van den Abbeele, AD
    Eisenberg, B
    Roberts, PJ
    Heinrich, MC
    Tuveson, DA
    Singer, S
    Janicek, M
    Fletcher, JA
    Silverman, SG
    Silberman, SL
    Capdeville, R
    Kiese, B
    Peng, B
    Dimitrijevic, S
    Druker, BJ
    Corless, C
    Fletcher, CDM
    Joensuu, H
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (07) : 472 - 480
  • [7] Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors
    Desai, Jayesh
    Shankar, Sridhar
    Heinrich, Michael C.
    Fletcher, Jonathan A.
    Fletcher, Christopher D.
    Manola, Judi
    Morgan, JeffreyA.
    Corless, Christopher L.
    George, Suzanne
    Tuncali, Kemal
    Silverman, Stuart G.
    Van den Abbeele, Annick D.
    van Sonnenberg, Eric
    Demetri, George D.
    [J]. CLINICAL CANCER RESEARCH, 2007, 13 (18) : 5398 - 5405
  • [8] Alternate Endpoints for Screening Phase II Studies
    Dhani, Neesha
    Tu, Dongsheng
    Sargent, Daniel J.
    Seymour, Lesley
    Moore, Malcolm J.
    [J]. CLINICAL CANCER RESEARCH, 2009, 15 (06) : 1873 - 1882
  • [9] Processes for quality improvements in radiation oncology clinical trials
    Fitzgerald, T. J.
    Urie, Marcia
    Ulin, Kenneth
    Laurie, Fran
    Yorty, Jeffrey
    Hanusik, Richard
    Kessel, Sandy
    Jodoin, Maryann Bishop
    Osagie, Gani
    Cicchetti, M. Giulia
    Pieters, Richard
    McCarten, Kathleen
    Rosen, Nancy
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 71 (01): : S76 - S79
  • [10] Gambhir SS, 2001, J NUCL MED, V42, p1S
1234